ANTIVIRAL TECHNOLOGIES, INC.: 10-Q filed 2011-11-15

Name: ANTIVIRAL TECHNOLOGIES, INC.: 10-Q filed 2011-11-15
Creator: ANTIVIRAL TECHNOLOGIES, INC.
License: https://creativecommons.org/licenses/by/4.0/

What ANTIVIRAL TECHNOLOGIES, INC. reported in its quarterly report filed 2011-11-15 (fiscal Q3 2011): 17 published measures, 48 facts as tagged in accession 0001137050-11-000370.

This filing

Form: 10-Q (quarterly report)
Filed: 2011-11-15
Fiscal period: fiscal Q3 2011
Accession: 0001137050-11-000370 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All ANTIVIRAL TECHNOLOGIES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2011-09-30	396,667	USD
At 2010-12-31	384,219	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2011-09-30	2,195,467	USD
At 2010-12-31	1,908,105	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2011-09-30	-1,798,800	USD
At 2010-12-31	-1,523,886	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2011-09-30	1,114	USD
At 2010-12-31	3,134	USD
At 2010-09-30	8,334	USD
At 2009-12-31	10,599	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	-90,355	USD	92
2011-01-01 to 2011-09-30	-273,810	USD	273
2007-09-13 to 2011-09-30	-1,806,982	USD	1479
2010-07-01 to 2010-09-30	-113,020	USD	92
2010-01-01 to 2010-09-30	-318,573	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	-90,296	USD	273
2007-09-13 to 2011-09-30	-970,835	USD	1479
2010-01-01 to 2010-09-30	-61,442	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	115,290	USD	273
2007-09-13 to 2011-09-30	1,415,658	USD	1479
2010-01-01 to 2010-09-30	81,434	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	-25,935	USD	273
2007-09-13 to 2011-09-30	-430,373	USD	1479
2010-01-01 to 2010-09-30	-21,271	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2011-09-30	3,198	USD
At 2010-12-31	4,074	USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2011-09-30	2,055	USD
At 2010-12-31	11,033	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2007-09-13 to 2011-09-30	-31,962	USD	1479

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2011-09-30	391,414	USD
At 2010-12-31	369,112	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2011-09-30	-144,858	USD
At 2010-12-31	-144,858	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2011-09-30	3,040	USD
At 2010-12-31	4,144	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	-93,275	USD	92
2011-01-01 to 2011-09-30	-274,914	USD	273
2007-09-13 to 2011-09-30	-1,803,942	USD	1479
2010-07-01 to 2010-09-30	-118,194	USD	92
2010-01-01 to 2010-09-30	-319,582	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	90,354	USD	92
2011-01-01 to 2011-09-30	272,133	USD	273
2007-09-13 to 2011-09-30	1,650,068	USD	1479
2010-07-01 to 2010-09-30	113,008	USD	92
2010-01-01 to 2010-09-30	317,613	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	959	USD	273
2007-09-13 to 2011-09-30	7,504	USD	1479
2010-01-01 to 2010-09-30	932	USD	273

Inspect the source

Entity: ANTIVIRAL TECHNOLOGIES, INC. / CIK 0001445226
Captured: 2026-09-23 02:47 UTC
SEC response SHA-256: 8eebaa08a3fdfe2277d78068fe27fc31b233085f2e48bbd10b68292209892301

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001445226.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))